Abbas Mirshafiey

Summary

Affiliation: Tehran University of Medical Sciences
Country: Iran

Publications

  1. ncbi Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 32:219-27. 2010
  2. ncbi Prostaglandins in pathogenesis and treatment of multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Iran
    Immunopharmacol Immunotoxicol 32:543-54. 2010
  3. ncbi TGF-beta as a promising option in the treatment of multiple sclerosis
    Abbas Mirshafiey
    Departmant of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Box 6446, Iran
    Neuropharmacology 56:929-36. 2009
  4. ncbi Novel promising therapeutic agents in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Recent Pat Inflamm Allergy Drug Discov 1:218-4. 2007
  5. ncbi The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Iran J Allergy Asthma Immunol 7:195-202. 2008
  6. ncbi Antioxidant therapy in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, Tehran University of Medical Sciences, Iran
    Immunopharmacol Immunotoxicol 31:13-29. 2009
  7. ncbi Venom therapy in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Medical Sciences, University of Tehran, Box 6446, Tehran 14155, Iran
    Neuropharmacology 53:353-61. 2007
  8. ncbi Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis
    A Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 29:49-61. 2007
  9. ncbi M2000: a revolution in pharmacology
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Med Sci Monit 11:PI53-63. 2005
  10. ncbi Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 27:255-65. 2005

Collaborators

  • Farhad Jadidi-Niaragh
  • Mohammad Reza Khorramizadeh
  • Salvatore Cuzzocrea
  • Farshid Saadat
  • Mohsen Hamedani
  • Alireza Razavi
  • Fariba Naderi Beni
  • G Mosayebi
  • Azita Hekmatdoost
  • Hossein Vatanpour
  • Monireh Mohsenzadegan
  • Fatemeh Fattahi
  • Mohammad Ansari
  • Mostafa Moin
  • Masoud Movahedi
  • Zahra Pourpak
  • A Ghazavi
  • S Namaki
  • P Ekhtiari
  • D Haghmorad
  • Reza Sedaghat
  • Abolghasem Djazayery
  • Kevan Jacobson
  • Mohammad R Eshraghian
  • Mohammad M Feizabadi
  • Samira M Yeganeh
  • Hamid R Nouri
  • Farhad Mehrabian
  • Mohammad Sedaghat
  • Mohammad Reza Khorramizaheh
  • Fatemeh Hadji-Ghasemi
  • Azar Berahmeh
  • Rosanna Di Paola
  • Mohammad Pezeshki

Detail Information

Publications26

  1. ncbi Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 32:219-27. 2010
    ..Moreover, we suggest that blockage of LT receptors by potent specific antagonists and/or agonists can be as a novel useful method in treatment of MS...
  2. ncbi Prostaglandins in pathogenesis and treatment of multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Iran
    Immunopharmacol Immunotoxicol 32:543-54. 2010
    ..Thus use of agonists or antagonists of PG receptors may be considered as a new therapeutic protocol in MS. In this review, we try to clarify the role of PGs in immunopathology and treatment of MS...
  3. ncbi TGF-beta as a promising option in the treatment of multiple sclerosis
    Abbas Mirshafiey
    Departmant of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Box 6446, Iran
    Neuropharmacology 56:929-36. 2009
    ..In this review, we will describe the regulatory and therapeutic effects of TGF-beta in multiple sclerosis...
  4. ncbi Novel promising therapeutic agents in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Recent Pat Inflamm Allergy Drug Discov 1:218-4. 2007
    ..This review provides a compilation of the more thoroughly studied of these novel immunotherapeutic agents and new aspects of designed molecular targets and patents which have recently evolved...
  5. ncbi The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Iran J Allergy Asthma Immunol 7:195-202. 2008
    ..In this review article, our aim is to clarify the role of ROS in immunopathogenesis of Rheumatoid arthritis...
  6. ncbi Antioxidant therapy in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, Tehran University of Medical Sciences, Iran
    Immunopharmacol Immunotoxicol 31:13-29. 2009
    ..In this review, our aim is to clarify the therapeutic efficacy of antioxidants in MS disease...
  7. ncbi Venom therapy in multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Medical Sciences, University of Tehran, Box 6446, Tehran 14155, Iran
    Neuropharmacology 53:353-61. 2007
    ..The aim of this review is to describe the recent findings regarding the role of venoms and their components in treatment of MS disease and that whether venom therapy could be recommended as a complementary treatment or not...
  8. ncbi Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis
    A Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 29:49-61. 2007
    ..CONCLUSIONS: These findings suggest that treatment with M2000 can reduce proteinuria, diminish antibody production, and suppress the progression of disease in a rat model of immune complex glomerulonephritis...
  9. ncbi M2000: a revolution in pharmacology
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Med Sci Monit 11:PI53-63. 2005
    ..The tolerability and the anti-inflammatory and immunosuppressive properties of a novel designed non-steroidal anti-inflammatory drug, M2000 (beta-D-mannuronic acid), were investigated in various experimental models...
  10. ncbi Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 27:255-65. 2005
    ..Collectively, our data suggest that M2000 may provide a novel therapeutic option for T-cell-mediated autoimmune diseases in animal models and possibly in humans...
  11. ncbi Treatment of experimental immune complex glomerulonephritis by sodium alginate
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, P O Box 6446, 14155 Tehran, Iran
    Vascul Pharmacol 43:30-5. 2005
    ....
  12. ncbi Chemoprevention by pyrimethamine
    Farshid Saadat
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 27:233-40. 2005
    ..1, 1, and 10 microg/ml) was 3.30%, 9.42%, and 11.32%, respectively. Our data suggest that pyrimethamine enables suppression of MMP-2 activity and induces apoptosis that could be assumed for chemoprevention therapy...
  13. ncbi Effect of pyrimethamine in experimental rheumatoid arthritis
    Farshid Saadat
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Med Sci Monit 11:BR293-9. 2005
    ....
  14. ncbi Treatment of experimental nephrotic syndrome with artesunate
    Alireza Razavi
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Int J Toxicol 26:373-80. 2007
    ..These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug...
  15. ncbi In vitro assessment of bee venom effects on matrix metalloproteinase activity and interferon production
    Mohsen Hamedani
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Iran J Allergy Asthma Immunol 4:9-14. 2005
    ..In contrast, its inhibitory effect was seen at high concentrations.It is concluded that, honeybee venom affects on MMP-2 activity and interferon beta production as well as cell proliferation in a time and dose-dependent manner...
  16. ncbi Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis
    Farhad Jadidi-Niaragh
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 33:545-67. 2011
    ..In this review, we intend to submit the comprehensive information about the immunobiology of various subsets of Tregs and their roles and function in immunopathophysiology of MS and its animal model, EAE...
  17. ncbi Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis
    Farhad Jadidi-Niaragh
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box 6446, Tehran 14155, Iran
    Neuropharmacology 59:180-9. 2010
    ..In this review, we try to clarify the role of histamine in pathogenesis of MS, as well as we evaluate the efficacy of histamine receptors agonists and antagonists in treatment of this disease...
  18. ncbi Therapeutic effect of EDTA in experimental model of multiple sclerosis
    G Mosayebi
    Department of Immunology, Arak University of Medical Sciences, Arak, Iran
    Immunopharmacol Immunotoxicol 32:321-6. 2010
    ..These data indicate that EDTA therapy can effectively attenuate EAE progression...
  19. ncbi Bee venom, immunostimulant or immunosuppressor? Insight into the effect on matrix metalloproteinases and interferons
    Mohsen Hamedani
    Department of Toxicology and Pharmacology, School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 27:671-81. 2005
    ..We conclude that time- and dose-dependent response as well as the type of treated cell line could determine the immunosuppressive and/or immunostimulant property of bee venom that could be effective in future therapeutic strategies...
  20. ncbi The effect of dietary oils on cecal microflora in experimental colitis in mice
    Azita Hekmatdoost
    Department of Human Nutrition, School of Health, Tehran University of Medical Sciences, Tehran, Iran
    Indian J Gastroenterol 27:186-9. 2008
    ..This study aimed to examine the effects of different dietary oils on intestinal microflora in an experimental model of colitis...
  21. ncbi Therapeutic approach to multiple sclerosis by novel oral drug
    Farhad Jadidi-Niaragh
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Box 6446, Iran
    Recent Pat Inflamm Allergy Drug Discov 5:66-80. 2011
    ..In this review, we will discuss about relevant patents and novel designed immunosuppressive and anti-inflammatory oral drugs promising for treatment of multiple sclerosis...
  22. ncbi Apoptotic efficacy and inhibitory effect of dexamethasone on matrix metalloproteinase
    Farshid Saadat
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Med Sci Monit 11:BR253-7. 2005
    ..CONCLUSIONS: Our findings suggest that dexamethasone is able to induce apoptosis and suppress MMP-2 activity. Collectively, dexamethasone might be assumed as an agent which could be recommended for chemopreventive purposes...
  23. ncbi Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment
    Fariba Naderi Beni
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Int Immunopharmacol 12:689-93. 2012
    ..This could be an explanation for the therapeutic effect of IFN-? in patients with CGD as NO acts as a bactericidal agent and plays a role in host defense mechanism instead of O(2)(-)...
  24. ncbi M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Immunopharmacol Immunotoxicol 26:611-9. 2004
    ..These data suggest that M-2000 therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrosis...
  25. ncbi Chemopreventive effect of M2000, a new anti-inflammatory agent
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    Med Sci Monit 10:PI105-9. 2004
    ..This study was undertaken to explore the role of a newly designed NSAID, M2000 (C6H10O7), as an anti-inflammatory drug in chemoprevention therapy under in vitro conditions...
  26. ncbi Treatment of experimental nephrosis by culture filtrate of Cryptococcus neoformans var. gattii (CneF)
    Abbas Mirshafiey
    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Iran
    Immunopharmacol Immunotoxicol 24:349-64. 2002
    ..These data suggest that CneF therapy can ameliorate proteinuria, hypercholesterolemia and suppress the progression of glomerular lesions in experimental model of nephrosis...